BCL2 and neoplasm: Previous studies have reported (50) that specific Nrf2 inhibition via KEAP1 (23) or Bcl-2 (51) strongly increased the susceptibility of tumor cell lines to different chemotherapeutics, including doxorubicin, cisplatin and etoposide.